Phase 2 Study of Zanubrutinib, Sonrotoclax, and Obinutuzumab for Untreated CLL
This study is testing a combination of three oral medications: zanubrutinib, sonrotoclax, and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not yet received treatment. The main goal is to see how well this combination works to control CLL/SLL, specifically by measuring how many cancer cells remain in the bone marrow after treatment. Researchers will also look at how safe the treatment is and how well people tolerate it. You may be able to join if you are 18 or older and have untreated CLL/SLL that meets specific criteria for treatment. The study plans to enroll 40 participants.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 40 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
At a glance
Conditions
NCT07674810
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
UT MD Anderson
Houston, Texasstudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Nitin Jain, MBBS · PRINCIPAL_INVESTIGATOR · UT MD Anderson
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0